Abstract

A REVIEW OF ANALYTICAL METHODS FOR DETERMINATION OF REPAGLINIDE IN PHARMACEUTICALS AND BIOLOGICAL MATRICES

Aleti. Raja Reddy and Ancha. Sushmitha*

ABSTRACT

Repaglinide is a novel insulin secretagogue being developed for the manageme nt of type 2 (non-insulin-dependent) diabetes mellitus. It stimulates release of insulin from the pancreatic beta-cell, but appears to bind to a different receptor site from sulphonylureas. Repaglinide lowers fasting and postprandial blood glucose levels in animals, healthy voluntee rs and patients with type 2 diabetes mellitus. Repaglinide is rapidly absorbed and elimina ted, which may allow a relatively fast onset and offset of action. Excretion occurs almost entirely by non-renal mechanisms. In comparative clinical trials in patients with type 2 diabetes mellitus, repaglinide 0.5 to 4 mg twice or 3 times daily before meals provided similar glycaemic control to glibenclamide (glyburide) 2.5 to 15 mg/day. Addition of repaglinide to existing metformin therapy resulted in improved glycaemic control. In contrast with glibenclamide, use of repaglinide allowed patients to miss a meal without apparently increasing the risk of hypoglycaemia. Thus repaglinide should be considered for use in any patient with type-2 diabetes mellitus whose blood glucose cannot be controlled by diet or exercise alone or as an adjunct in patients whose glucose levels are inadequently controlled on metformin alone. This assessment different analytical methods such as RP-HPLC, HPTLC, CAPILLARY ELECROPHORESIS, UV-SPECTROSCOPY.

Keywords: Repaglinide, type-2 diabetes mellitus, RP- HPLC, HPTLC, UV-SPECTROSCOPY.